Maynard Um
-
-
-
-
-
-
-
Intellia short interest rises most among biotech stocks in latest period - Baird
-
-
-
-
-
-
-
Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) PT Lowered to $44 at Baird
-
-
-
-
-
-
-
Citizens Reiterates Market Outperform on CRISPR (CRSP), Notes In-vivo Editing Progress
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) PT Raised to $56 at Barclays
-
-
-
-
-
-
-
Brookline Capital Markets Reiterates Buy Rating on CRISPR Therapeutics (CRSP)
-
-
-
-
-
-
-
Eli Lilly and Verve's gene-editing M&A deal 'an important milestone' - Citizens JMP
-
421,795 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

